华东医药
(000963)
| 流通市值：641.74亿 | | | 总市值：642.52亿 |
| 流通股本：17.52亿 | | | 总股本：17.54亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 31,477,654,750.5 | 20,965,065,605.67 | 10,410,809,128.72 | 40,623,782,520.43 |
| 营业收入 | 31,477,654,750.5 | 20,965,065,605.67 | 10,410,809,128.72 | 40,623,782,520.43 |
| 二、营业总成本 | 28,288,811,654.13 | 18,876,799,219.53 | 9,331,357,509.92 | 37,081,915,122.91 |
| 营业成本 | 21,231,803,408.72 | 14,109,803,647.16 | 7,076,397,110.06 | 27,461,731,573.59 |
| 税金及附加 | 163,791,954.73 | 111,008,570.22 | 56,334,556.14 | 232,590,269.39 |
| 销售费用 | 4,727,512,478.83 | 3,274,822,873.39 | 1,574,261,928.29 | 6,645,411,414.21 |
| 管理费用 | 1,179,023,165.24 | 714,633,116.91 | 335,169,160.39 | 1,420,188,961.59 |
| 研发费用 | 948,662,894.53 | 643,106,566.65 | 281,639,751.64 | 1,270,803,119.96 |
| 财务费用 | 38,017,752.08 | 23,424,445.2 | 7,555,003.4 | 51,189,784.17 |
| 其中:利息费用 | 86,594,008.13 | 55,550,660.47 | 23,050,131.41 | 119,514,554.96 |
| 其中:利息收入 | 80,012,995.89 | 53,142,421.17 | 24,409,865.24 | 94,045,345.71 |
| 加:公允价值变动收益 | - | - | -25,364.49 | -13,756,372.8 |
| 加:投资收益 | -86,710,253.53 | -47,845,863.81 | -47,163,448.93 | -219,713,034.52 |
| 资产处置收益 | 2,177,150.46 | 4,927,280.24 | 1,521,275.31 | 4,319,797.54 |
| 资产减值损失(新) | - | - | - | -6,519,844.03 |
| 信用减值损失(新) | -57,939,915.17 | -57,939,915.37 | - | -25,763,586.64 |
| 其他收益 | 168,982,096.89 | 93,707,046.82 | 38,311,729.18 | 172,492,861.66 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 3,215,352,175.02 | 2,081,114,934.02 | 1,072,095,809.87 | 3,452,927,218.73 |
| 加:营业外收入 | 7,442,671.2 | 5,221,955.01 | 1,295,600.39 | 50,548,825.6 |
| 减:营业外支出 | 88,911,294.16 | 37,784,277.75 | 5,202,610.91 | 37,490,279.21 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 3,133,883,552.06 | 2,048,552,611.28 | 1,068,188,799.35 | 3,465,985,765.12 |
| 减:所得税费用 | 571,279,294.45 | 360,337,560.24 | 207,943,278.46 | 619,588,815.15 |
| 六、净利润 | 2,562,604,257.61 | 1,688,215,051.04 | 860,245,520.89 | 2,846,396,949.97 |
| 持续经营净利润 | 2,562,604,257.61 | 1,688,215,051.04 | 860,245,520.89 | 2,846,396,949.97 |
| 归属于母公司股东的净利润 | 2,562,326,688.45 | 1,696,020,589.2 | 862,411,560.96 | 2,838,860,542.8 |
| 少数股东损益 | 277,569.16 | -7,805,538.16 | -2,166,040.07 | 7,536,407.17 |
| (一)基本每股收益 | 1.46 | 0.97 | 0.49 | 1.62 |
| (二)稀释每股收益 | 1.46 | 0.97 | 0.49 | 1.62 |
| 八、其他综合收益 | 17,675,896.3 | -6,285,502.28 | 40,589,535.1 | 50,506,468.03 |
| 归属于母公司股东的其他综合收益 | 17,675,896.3 | -6,285,502.28 | 40,589,535.1 | 50,506,468.03 |
| 九、综合收益总额 | 2,580,280,153.91 | 1,681,929,548.76 | 900,835,055.99 | 2,896,903,418 |
| 归属于母公司股东的综合收益总额 | 2,580,002,584.75 | 1,689,735,086.92 | 903,001,096.06 | 2,889,367,010.83 |
| 归属于少数股东的综合收益总额 | 277,569.16 | -7,805,538.16 | -2,166,040.07 | 7,536,407.17 |
| 公告日期 | 2024-10-25 | 2024-08-16 | 2024-04-26 | 2024-04-18 |
| 审计意见(境内) | | | | 标准无保留意见 |